Artielle ImmunoTherapeutics Company
Artielle ImmunoTherapeutics develops recombinant T-cell receptor ligands to treat T-cell-mediated inflammatory diseases.
Industry:
PharmTech
Technology:
Medical Devices
Funding Status:
Early Stage Venture
Estimated Revenue:
$1M to $10M
Headquarters:
San Mateo, California, United States
Employee Number:
1-10
Founded Date:
2004